Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data
Xconomy
SEPTEMBER 18, 2018
[ Updated, 2:45 pm ET, see below ] There is another update today in the competitive race to treat nonalcoholic steatohepatitis (NASH), an increasingly common liver disease with no FDA-approved therapies.
Let's personalize your content